XOMA Royalty was a traditional biotech company for over 35 years. In 2017, we transformed our business operations, exiting the traditional biotech activities of discovery, research and development.
Due to our legacy, we have one of the largest phage display libraries in the industry and several early stage monoclonal antibodies that are available for licensing:
Phage Display Platform
A premier antibody discovery and development platform
MORE +
Ebopiprant
Ebopiprant (also known as OBE022) is an orally bioavailable, selective small molecule antagonist of the prostaglandin F2α receptor.
MORE +
Anti-prolactin Antibody
A first-in-class allosteric inhibitor of prolactin action
MORE +
XMetA Portfolio
A novel partial activator of the human insulin receptor
MORE +
